adivo, a German biotech company specializing in generating species-specific therapeutic antibodies for companion animals, received a seed financing of undisclosed amount.
Backers included High-Tech Gründerfonds (HTGF), Occident Group AG and MorphoSys AG.
The company intends to use the funds to advance its therapeutic antibody programs forward as well as to continuously improve the technology.
Led by Dr. Ladetzki-Baehs, Managing Director, adivo develops new technologies to expand the range of therapeutic options for pet cancer and chronic inflammatory conditions. In 2018, in order to facilitate and complete the realization of the adivo founding project, MorphoSys granted adivo the rights to the newly built fully synthetic phage display antibody library, mimicking the canine immune globulin repertoire.
The company is located in the Innovation and Start-Up Center for Biotechnology (IZB) in Martinsried near Munich.